RedHill Biopharma (RDHL) Revenue (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Revenue data on file, last reported at $1.8 million in Q2 2023.

• On a quarterly basis, Revenue fell 90.21% year-over-year to $1.8 million in Q2 2023; TTM through Jun 2023 was $35.7 million, a 52.42% decrease from a year earlier, with the FY2025 full-year figure at $286000.0, down 96.44% from the prior year.
• Revenue for Q2 2023 stood at $1.8 million, down from $3.6 million in the prior quarter.
• Over the last five years, Revenue for RDHL reached as high as $22.1 million in Q4 2021 and fell as low as $1.1 million in Q1 2020.
• Historically, Revenue has averaged $12.4 million across 5 years, with a median of $15.3 million in 2022.
• Across the five-year window, Revenue surged 1848.39% in 2021 and sank 90.21% in 2023, its largest moves.
• Year by year, Revenue stood at $1.6 million in 2019, then surged by 1249.75% to $21.5 million in 2020, then climbed by 2.84% to $22.1 million in 2021, then tumbled by 42.01% to $12.8 million in 2022, then sank by 85.97% to $1.8 million in 2023.
• Per Business Quant data, the three most recent Revenue figures were $1.8 million in Q2 2023, $3.6 million in Q1 2023, and $12.8 million in Q4 2022.